Last updated: February 15, 2026
Overview of the Product
NDC 00093-9222 corresponds to Lemtrada (alemtuzumab), a monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (MS). Approved in 2014, Lemtrada is administered via intravenous infusion with a unique dosing regimen: four annual courses, each consisting of five days of infusions initially, followed by a second course of three days after 12 months, then no further doses unless necessary.
Market Size and Growth Drivers
- Prevalence of Multiple Sclerosis: Over 2.3 million individuals worldwide have MS, with approximately 1 million in the U.S. (source: National MS Society).
- Patient Population for Lemtrada: Typically prescribed for patients with highly active relapsing MS or those who have failed other disease-modifying therapies (DMTs).
- Market Penetration: Lemtrada's market share remains limited compared to oral DMTs like Tecfidera or oral S1P receptor modulators, due to administration complexity and safety concerns.
Competitive Landscape
| Drug |
Class |
Approvals / Indications |
Approximate Market Share (2022) |
| Lemtrada (alemtuzumab) |
Monoclonal antibody |
Highly active relapsing MS |
2-3% |
| Tecfidera (dimethyl fumarate) |
Oral DMT |
Relapsing MS |
25-30% |
| Aubagio (teriflunomide) |
Oral DMT |
Relapsing MS |
10-15% |
| Kesimpta (ofatumumab) |
Monoclonal antibody |
Relapsing MS |
5-7% |
Pricing and Revenue
- List Price: Approximately $128,000 per course (per year), based on U.S. wholesale acquisition costs (WAC) data.
- Cost per Patient: Since administration involves multiple doses, the total treatment cost per year can range from $128,000 to $200,000, considering ancillary costs.
- Revenue Estimates (2022): Estimated U.S. sales of Lemtrada are approximately $200 million, accounting for limited market penetration and administration constraints (source: IQVIA).
Pricing Trends and Projections
| Year |
Price per Course |
Expected Changes |
Rationale |
| 2023 |
$128,000 |
Stable |
No major pricing adjustments announced. |
| 2024 |
$130,000 |
Slight increase |
General inflation, sustained demand. |
| 2025 |
$132,000 |
Stable |
Expected market stabilization. |
| 2026 |
$135,000 |
Slight increase |
Anticipated inflation, potential new competitors. |
Market Entry Barriers
- Safety profile concerns: Risks of infusion reactions, autoimmune conditions, and infections limit widespread usage.
- Administration complexity: Intravenous infusion requires specialized facilities, deterring some physicians.
- Pricing pressures: Payers are increasingly scrutinizing high-cost therapies, influencing reimbursement.
Regulatory and Policy Impact
- FDA Post-market Monitoring: Continues to scrutinize safety data which may impact prescribing patterns.
- Insurance reimbursement: Patients often need prior authorization, with commercial payers negotiating discounts.
- Potential biosimilar development: Pending patents and biosimilar candidates could exert downward pressure after exclusivity expires (expected around 2030).
Long-term Price and Market Outlook
- Market Growth: Limited growth expected, given the niche positioning and safety profile.
- Price trends: Marginal increases aligned with inflation and market dynamics.
- Potential catalysts: Expanded indications, biosimilar entry, or new formulations could reshape pricing strategies.
Key Takeaways
- NDC 00093-9222 (Lemtrada) generates approximately $200 million in U.S. sales.
- The product maintains a premium pricing model at roughly $128,000 per treatment course.
- Market share remains limited due to administration challenges and safety considerations.
- Future price increases are expected to stay within a modest range, influenced by inflation and payer negotiations.
- The competitive landscape includes oral DMTs and emerging biosimilars, which could pressure prices post-2030.
FAQs
-
What are the main factors limiting Lemtrada’s market penetration?
- Safety concerns, administration complexity, and payer restrictions.
-
How does Lemtrada’s pricing compare to other MS therapies?
- It remains among the higher-cost MS treatments at approximately $128,000 per course, with oral therapies often priced slightly lower or comparable.
-
What are the prospects for biosimilars impacting Lemtrada’s price?
- Biosimilars could emerge post-patent expiry (~2030), potentially reducing prices.
-
How does safety profile influence pricing?
- Post-market safety issues can restrict use, limit reimbursement, and influence perceptions, thereby constraining pricing power.
-
What is the potential for new indications to affect the market?
- Expanded indications could increase patient population size, but safety and efficacy data are critical factors.
Citations
[1] National Multiple Sclerosis Society. (2022). MS Data & Statistics.
[2] IQVIA. (2022). US Pharma Market Insights.
[3] FDA. (2014). Lemtrada Approval Announcement.
[4] GoodRx. (2023). Lemtrada Price & Cost.
